Molecular profiling predicts clinical outcome in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin.

被引：0
|
作者：
Yun, J [1 ]
Zhang, W [1 ]
Park, D [1 ]
Yang, D [1 ]
Press, O [1 ]
Gordon, M [1 ]
Mallik, N [1 ]
Lenz, HJ [1 ]
机构：
[1] Univ So Calif, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：249S / 249S
页数：1
相关论文
共 50 条
  • [1] Intratumoral mRNA levels predict clinical outcome in patients with metastatic colorectal cancer treated in a prospective clinical trial with 5-FU and oxaliplatin.
    Yang, D.
    Vallböhmer, D.
    Zhang, W.
    Iqbal, S.
    El-Khoueiry, A.
    Gordon, M.
    Park, D.
    Azuma, M.
    Groshen, S.
    Danenberg, K. D.
    Lenz, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 543S - 543S
  • [2] AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
    J B Kjersem
    M Thomsen
    T Guren
    J Hamfjord
    G Carlsson
    B Gustavsson
    T Ikdahl
    G Indrebø
    P Pfeiffer
    O Lingjærde
    K M Tveit
    Y Wettergren
    E H Kure
    [J]. The Pharmacogenomics Journal, 2016, 16 : 272 - 279
  • [3] AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
    Kjersem, J. B.
    Thomsen, M.
    Guren, T.
    Hamfjord, J.
    Carlsson, G.
    Gustavsson, B.
    Ikdahl, T.
    Indrebo, G.
    Pfeiffer, P.
    Lingjaerde, O.
    Tveit, K. M.
    Wettergren, Y.
    Kure, E. H.
    [J]. PHARMACOGENOMICS JOURNAL, 2016, 16 (03): : 272 - 279
  • [4] Effect of celecoxib on neurotoxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin (CIFOX).
    Agafitei, RD
    Schneider, S
    Iqbal, S
    Yang, D
    Groshen, S
    Lenz, HJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 270S - 270S
  • [5] Polymorphism in sodium-channel alpha 1-subunit (SCN1A) predicts response, TTP, survival, and toxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin.
    Nagashima, F.
    Zhang, W.
    Yang, D.
    Gordon, M.
    Schultheis, A.
    Fazzone, W.
    Azuma, M.
    El-Khoueiry, A.
    Iqbal, S.
    Lenz, H. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 154S - 154S
  • [6] Oxaliplatin with 5-FU or as a single agent in advanced/metastatic colorectal cancer
    Mitchell, EP
    [J]. ONCOLOGY-NEW YORK, 2000, 14 (12): : 30 - 32
  • [7] Oxaliplatin rechallenge in patients with metastatic colorectal cancer prior treatment with oxaliplatin.
    Kim, Jeong-Eun
    Hong, Yong Sang
    Kim, Kyu-Pyo
    Park, Seong Joon
    Lee, Jae-Lyun
    Kim, Tae Won
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [8] Oxaliplatin/5-FU chemotherapy without leucovorin in metastatic colorectal cancer.
    Shim, BY
    Cho, HJ
    Yang, JM
    Kim, HJ
    Kim, JK
    Kim, HK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 302S - 302S
  • [9] Significance of thymidine phosphorylase, VEGF, and p53 in predicting response for metastatic colorectal cancer patients receiving 5-FU/LV + irinotecan or oxaliplatin.
    Oh, HS
    Ahn, MJ
    Choi, JH
    Kim, IS
    Lee, YY
    Choi, IY
    Lee, HW
    Park, CK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 302S - 302S
  • [10] Compliance and toxicity in metastatic colorectal carcinoma patients treated with capecitabine versus 5-FU associated with oxaliplatin or irinotecan
    Raimondi, C.
    Longo, F.
    Tomao, S.
    Ricciardi, S.
    Rosati, S.
    Messina, C. G. M.
    Cerbone, L.
    Spalletta, B.
    Russillo, M.
    Di Seri, M.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI43 - XI43
12345